Comparison of serum levels of inflammatory markers and allelic variant of interleukin-6 in patients with acute coronary syndrome and stable angina pectoris

Coronary Artery Disease

Volumn 19, Issue 1, 2008, Pages 15-19

  Ozdemir, Oznur ^a   Gundogdu, Fuat ^a,b   Karakelleoglu, Sule ^a   Sevimli, Serdar ^a   Pirim, Ibrahim ^a   Acikel, Mahmut ^a   Arslan, Sakir ^a   Serdar, Serkan ^a  

^a ATATURK UNIVERSITY   (Turkey)

^b NONE   (Turkey)

Author keywords

Coronary artery disease; Gene polymorphism; Interleukin 6

Indexed keywords

C REACTIVE PROTEIN; INTERLEUKIN 6;

ACUTE CORONARY SYNDROME; ADULT; ANGIOCARDIOGRAPHY; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; FEMALE; GENOTYPE; HEMODYNAMICS; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN POLYMORPHISM; STABLE ANGINA PECTORIS;

ACUTE CORONARY SYNDROME; ADULT; AGED; ANGINA PECTORIS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; FEMALE; HUMANS; INFLAMMATION; INTERLEUKIN-6; MALE; MIDDLE AGED; MUTATION; POLYMORPHISM, GENETIC;

EID: 40349105705     PISSN: 09546928     EISSN: None     Source Type: Journal    
DOI: 10.1097/MCA.0b013e3282f27bf7     Document Type: Article

References (28)

1. Gupta N, Khan F, Tripathi M, Singh VP, Tewari S, Ramesh V, et al. Absence of factor V Leiden (G1691A) mutation, FII G20210A allele in coronary artery disease in North India. Indian J Med Sci 2003; 57:535-542.
2. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med 1999; 340:115-126.
3. Yudkin JS, Stehouwer CD, Emeis JJ, Coppack SW. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol 1999; 19:972-978.
4. Heinrich J, Schulte H, Schonfeld R, Kohler E, Assmann G. Association of variables of coagulation, fibrinolysis and acute-phase with atherosclerosis in coronary and peripheral arteries and those arteries supplying the brain. Thromb Haemost 1995; 73:374-379.
5. Liuzzo G, Biasucci LM, Gallimore JR, Grillo RL, Rebuzzi AG, Pepys MB, et al. The prognostic values of C-reactive protein and serum amyloid a protein in severe unstable angina. N Engl J Med 1994; 331:417-424.
6. Thompson SG, Kienast J, Pyke SD, Haverkate F, van de Loo JC. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. N Engl J Med 1995; 332:635-641.
7. Biasucci LM, Vitelli A, Liuzzo G, Altamura S, Caligiuri G, Monaco C, et al. Elevated levels of interleukin-6 in unstable angina. Circulation 1996; 94:874-877.
8. Ridker PM, Rifai N, Stampfer MJ, Hennekens CH. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 2000; 101:1767-1772.
9. Fishman D, Faulds G, Jeffery R, Mohamed-Ali V, Yudkin JS, Humphries S, et al. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemiconset juvenile chronic arthritis. J Clin Invest 1998; 102:1369-1376.
10. Seino Y, Ikeda U, Ikeda M, Yamamoto K, Misawa Y, Hasegawa T, et al. Interleukin-6 gene transcripts are expressed in human atherosclerotic lesions. Cytokine 1994; 6:87-91.
11. Ellis K, Kapadia SR. Stable angina. In: Griffin BP, Topol EJ, editors. Manual of cardiovascular medicine. 2nd ed. Philadelphia: Lippincott, Williams & Wilkins; 2004. p. 74.
12. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002; 105:1135-1143.
13. Liuzzo G, Biasucci LM. Markers of inflammation, in acute coronary syndromes. In: Théroux P, editor. A companion to Braunwald's heart disease. Philadelphia: WB Saunders; 2003. pp. 209-225.
14. Humphries SE, Luong LA, Ogg MS, Hawe E, Miller GJ. The interleukin-6-174 G/C promoter polymorphism is associated with risk of coronary heart disease and systolic blood pressure in healthy men. Eur Heart J 2001; 22:2243-2252.
15. Chapman CM, Beilby JP, Humphries SE, Palmer LJ, Thompson PL, Hung J. Association of an allelic variant of interleukin-6 with subclinical carotid atherosclerosis in an Australian community population. Eur Heart J 2003; 24:1494-1499.
16. Burzotta F, Iacoviello L, Di Castelnuovo A, Glieca F, Luciani N, Zamparelli R, et al. Relation of the -174 G/C polymorphism of interleukin-6 to interleukin-6 plasma levels and to length of hospitalization after surgical coronary revascularization. Am J Cardiol 2001; 88:1125-1128.
17. Lindmark E, Diderholm E, Wallentin L, Siegbahn A. Relationship between interleukin 6 and mortality in patients with unstable coronary artery disease: effects of an early invasive or noninvasive strategy. JAMA 2001; 286:2107-2113.
18. Deliargyris EN, Raymond RJ, Theoharides TC, Boucher WS, Tate DA, Dehmer GJ. Sites of interleukin-6 release in patients with acute coronary syndromes and in patients with congestive heart failure. Am J Cardiol 2000; 86:913-918.
19. Mazzone A, De Servi S, Vezzoli M, Fossati G, Mazzucchelli I, Gritti D, et al. Plasma levels of interleukin 2, 6, 10 and phenotypic characterization of circulating T lymphocytes in ischemic heart disease. Atherosclerosis 1999; 145:369-374.
20. Date H, Imamura T, Sumi T, Ishikawa T, Kawagoe J, Onitsuka H, et al. Effects of interleukin-6 produced in coronary circulation on production of C-reactive protein and coronary microvascular resistance. Am J Cardiol 2005; 95:849-852.
21. Bogaty P, Poirier P, Simard S, Boyer L, Solymoss S, Dagenais GR. Biological profiles in subjects with recurrent acute coronary events compared with subjects with long-standing stable angina. Circulation 2001; 103:3062-3068.
22. Tappia PS, Troughton KL, Langley-Evans SC, Grimble RF. Cigarette smoking influences cytokine production and antioxidant defences. Clin Sci 1995; 88:485-489.
23. Saleh N, Svane B, Jensen J, Hansson LO, Nordin M, Tornvall P. Stent implantation, but not pathogen burden, is associated with plasma C-reactive protein and interleukin-6 levels after percutaneous coronary intervention in patients with stable angina pectoris. Am Heart J 2005; 149:876-882.
24. Kordula T, Guttgemann I, Rose-John S, Roeb E, Osthues A, Tschesche H, et al. Synthesis of tissue inhibitor of metalloproteinase-1 (TIMP-1) in human hepatoma cells (HepG2). Up-regulation by interleukin-6 and transforming growth factor beta 1. FEBS Lett 1992; 313:143-147.
25. Roeb E, Graeve L, Mullberg J, Matern S, Rose-John S. TIMP-1 protein expression is stimulated by IL-1 beta and IL-6 in primary rat hepatocytes. Ann N Y Acad Sci 1995; 762:462-464.
26. Rauramaa R, Vaisanen SB, Luong LA, Schmidt-Trucksass A, Penttila IM, Bouchard C, et al. Stromelysin-1 and interleukin-6 gene promoter polymorphisms are determinants of asymptomatic carotid artery atherosclerosis. Arterioscler Thromb Vasc Biol 2000; 20:2657-2662.
27. Fisman EZ, Benderly M, Esper RJ, Behar S, Boyko V, Adler Y, et al. Interleukin-6 and the risk of future cardiovascular events in patients with angina pectoris and/or healed myocardial infarction. Am J Cardiol 2006; 98:14-18.
28. Kwaijtaal M, van Diest R, Bar FW, van der Ven AJ, Bruggeman CA, de Baets MH, et al. Inflammatory markers predict late cardiac events in patients who are exhausted after percutaneous coronary intervention. Atherosclerosis 2005; 182:341-348.